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Clinical trials are central to Cancer Research UK’s pur-
pose of carrying out world-class research to improve
our understanding of how to prevent, diagnose and treat
cancer.
The UK leads the world in the percentage of cancer
patients entering clinical trials. In 2009, this figure
reached an all time high of 16.8% of NHS cancer
patients, of which ¾ entered a Cancer Research UK
(CR-UK) supported trial (n=31,000 patients). Conse-
quently, CR-UK has a major impact on the availability
of treatment trials for UK cancer patients.
The strengths and limitations of randomised con-
trolled trials have been discussed at length in the medi-
cal literature. In his 2008 Harveian Oration entitled ‘On
the evidence for decisions about the use of therapeutic
interventions’, Professor Sir Michael Rawlins made a
plea for investigators to continue to develop and
improve their methodologies and for decision makers to
avoid adopting entrenched positions about the nature of
evidence. The clinical trials community has responded
by proposing innovative trial designs and funders are
considering how to respond to the challenges of funding
trials with novel designs.
Multi-arm, multi-stage trial designs, for example, can
increase the chance of a single trial providing a positive
results and saves time and potentially money compared
to separate sequential trials. CR-UK already funds sev-
eral trials of this design, including STAMPEDE in pros-
tate cancer and ICON 6 in ovarian cancer. We also
fund trial the AML16 trial in Acute Myeloid Leukaemia
which adopts a complex design to evaluate a number of
agents concurrently dependent on the characteristics of
patient sub-groups and their response to treatment. The
RATH-L trial in Non-Hodgkin’s Lymphoma adopts
another innovative design, evaluating both the use of
PET scans to determine treatment pathways and sub-
randomisations to less or more intensive treatments.
Trials such as these present issues that funders need to
adapt to, including (1) educating our funding commit-
tees, (2) developing processes for the continual assess-
ment of treatments being discarded or introduced, and
(3) consideration of optimal models. The measures CR-
UK has taken to adopt an inclusive approach to innova-
tive trial designs will be described.
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